Kidney Cancer Research Consortium May Advance Progress in the Field

Commentary
Video

The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.

In a conversation with CancerNetwork® at the 2025 Kidney Cancer Research Summit, Eric Jonasch, MD, outlined the function of the Kidney Cancer Research Consortium, a program designed to facilitate research in diseases such as renal cell carcinoma. Jonasch highlighted the scope and features of the Kidney Cancer Research Consortium as part of a presentation at the meeting.

According to Jonasch, a professor in the Department of Genitourinary Medical Oncology of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, this program includes 7 institutions that collaborate on various hypothesis-testing clinical trials assessing novel therapeutic strategies in kidney cancer. He stated that researchers across these institutions may be able to lead more mechanistic and scientifically driven investigations while leveraging correlative samples and quality-of-life data as part of their efforts.

Transcript:

My presentation today was about the Kidney Cancer Research Consortium, which is a DOD KCRP [US Department of Defense Kidney Cancer Research Program]–funded program. This is the congressionally designated medical research program, and they then generated a program for renal cell carcinoma research, which then had various projects. One of those projects is to generate a research consortium, which I now lead.

This is a 7-institution consortium, and our goal is to be able to run tissue-rich, data-rich, hypothesis-testing clinical trials with novel agents. We’ve been doing this now for over 4 years. We now have a portfolio of 10 clinical trials that have either completed, are in progress, or [are] about to open. We’ve been very excited about the results so far.

What we’re able to do here is ask more mechanistic and scientifically driven questions. We’re able to collect correlative samples like circulating tumor DNA samples, tissue samples, as well as quality-of-life data on these clinical trials. [We can] also then do trial-by-trial comparisons, so we essentially can acquire more information from a smaller number of patients in a [smaller] amount of time.

Reference

Jonasch E. Building the infrastructure for discovery: a clinical trial consortium to accelerate kidney cancer research. Presented at: 2025 Kidney Cancer Research Summit; July 17-18, 2025; Boston, MA.

Recent Videos
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Although a similar proportion achieved MRD negativity at the 10 to the –6 power, not enough studies have analyzed MRD at this level for multiple myeloma.
Determining the molecular characteristics of one’s disease may influence the therapy employed in the first line as well as subsequent settings.
Unique toxicities presented with talquetamab tend to get progressively better as the treatment course continues, according to Prerna Mewawalla, MD.
Modification of REMS programs may help patients travel back to community practices sooner, according to Suman Kambhampati, MD.
Related Content